GlassScriptPhysician profile
Vanessa K Heimbach
NPI 1437113768
$4,407.46
in general payments reported to CMS, 2019-2025
21 companies · $879 in 2025
The $879 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $1,317 · 2023: $786 · 2024: $771 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,436.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,296.73 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,000.53 | 2021-2025 | Nucala |
| Optinose US, INC. | $671.06 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $403.17 | 2021-2025 | Dupixent, Libtayo |
| Csl Behring | $215.70 | 2022-2024 | Haegarda |
| Organogenesis INC. | $161.30 | 2022-2023 | Puraply |
| Amgen INC. | $117.99 | 2021-2025 | Tezspire |
| Biohaven Pharmaceutical Holding Company LTD. | $111.71 | 2022 | |
| Acclarent, INC | $67.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.94 | 2021-2025 | Keytruda |
| Phathom Pharmaceuticals, INC. | $44.79 | 2024-2025 | Voquezna |
| Intersect Ent, INC. | $42.30 | 2021 | |
| Medtronic, INC. | $39.76 | 2024 | Nim Vital, Ligasure |
| Neurent Medical Limited | $32.85 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Preceptis Medical, INC. | $28.64 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $27.56 | 2024-2025 | |
| Stryker Corporation | $25.38 | 2021 | |
| Paratek Pharmaceuticals, INC. | $24.00 | 2025 | Xhance |
| Biohaven Pharmaceuticals, INC. | $19.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.10 | 2025 | Tezspire |
| Alk-Abello, INC | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Heimbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.